Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.43 |
| ▸ | HTR5A | P47898 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3047523 | 1.00 | HRH3 (0.48) | HRH3HDAC1SLC2A1HTR5AEPHX1 | |
| Trifluoroacetic Acid SCHEMBL3039719 | 0.95 | MEN1 (0.43) | HRH3HDAC1SLC2A1HTR5AMEN1 | |
| Trifluoroacetic Acid SCHEMBL3041840 | 0.89 | CCR2 (0.38) | HRH3HDAC1SLC2A1HTR5AMEN1 | |
| Trifluoroacetic Acid SCHEMBL1876885 | 0.87 | HDAC1 (0.39) | HRH3HDAC1SLC2A1EPHX1MEN1 | |
| Trifluoroacetic Acid SCHEMBL1879960 | 0.87 | HDAC1 (0.39) | HRH3HDAC1SLC2A1EPHX1MEN1 | |
| Trifluoroacetic Acid SCHEMBL3047584 | 0.87 | CCR2 (0.38) | HRH3HDAC1SLC2A1HTR5AEPHX1 | |
| Trifluoroacetic Acid SCHEMBL3046770 | 0.87 | CCR2 (0.38) | HRH3HDAC1SLC2A1HTR5AEPHX1 | |
| Trifluoroacetic Acid SCHEMBL3050294 | 0.87 | HDAC6 (0.42) | HDAC1SLC2A1HTR5AEPHX1MEN1 | |
| Trifluoroacetic Acid SCHEMBL3050323 | 0.86 | SLC2A1 (0.51) | HDAC1SLC2A1HTR5AMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL3046203 | 0.85 | HTR5A (0.46) | SLC2A1HTR5AEPHX1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | HRH3 406/4885HDAC1 2221/4885SLC2A1 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.